Clinical evidence of the relationship between aspirin and breast cancer risk (Review)
In the search for new therapeutic alternatives against cancer, either as a preventive treatment or for advanced stages, it is common to appeal to well-known drugs used for the treatment of other diseases that may interfere with the metabolic pathways involved in carcinogenesis. Non-steroidal anti-in...
Gespeichert in:
| Veröffentlicht in: | Oncology reports 2014-08, Vol.32 (2), p.451-461 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 461 |
|---|---|
| container_issue | 2 |
| container_start_page | 451 |
| container_title | Oncology reports |
| container_volume | 32 |
| creator | JACOBO-HERRERA, NADIA J PÉREZ-PLASENCIA, CARLOS CAMACHO-ZAVALA, ELIZABETH GONZÁLEZ, GABRIELA FIGUEROA URRUTIA, EDUARDO LÓPEZ GARCÍA-CASTILLO, VERÓNICA ZENTELLA-DEHESA, ALEJANDRO |
| description | In the search for new therapeutic alternatives against cancer, either as a preventive treatment or for advanced stages, it is common to appeal to well-known drugs used for the treatment of other diseases that may interfere with the metabolic pathways involved in carcinogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) display anticancer activity through the inhibition of the COX-2 enzyme, triggering processes such as apoptosis, a reduction in proliferation and inhibition of carcinogenesis. Breast cancer is a neoplasm with the highest incidence and mortality rate among young women worldwide. Epidemiologic data have shown that drugs such as NSAIDs, particularly aspirin, reduce the relative risk of breast cancer. However, in the subgroup of responsive patients, dose, time and frequency of use have not yet been established. Here, we review the reports published during the last 10 years regarding the relationship between breast cancer and aspirin. |
| doi_str_mv | 10.3892/or.2014.3270 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1932680761</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A410769144</galeid><sourcerecordid>A410769144</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-dccd72b2a6514dc33135a876ed2dce7edd27eec7126e80894253dd2e7d0a8d5d3</originalsourceid><addsrcrecordid>eNptkVtLxDAQhYMo3t98loAgCnbNrU37uCzeQBBEwbeQTaZutNvUpKv478266w1kBmYYvjNDchDao2TAy4qd-jBghIoBZ5KsoE0qK5oxwelq6gmjGef5wwbaivGJkIQU1TraYKJiUhRyE92PGtc6oxsMr85CawD7GvcTwAEa3Tvfxonr8Bj6N4AW69i54FJtLR4H0LHHRidRwMHFZ3x0m7bA2_EOWqt1E2F3WbfR_fnZ3egyu765uBoNrzMjyqLPrDFWsjHTRU6FNZxTnutSFmCZNSDBWiYBjKSsgJKUlWA5TzOQlujS5pZvo4PF3i74lxnEXj35WWjTSUUrzoqSyIL-UI-6AeXa2vdBm6mLRg0FTUhFhUjU4B8qhYWpM76F2qX5H8HhL8EEdNNPom9mn5_2FzxZgCb4GAPUqgtuqsO7okTNPVQ-qLmHau5hwveXj5qNp2C_4S_Tfg7HLvngrI_fjA8ZZxlJKXLKPwA2f6FU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932680761</pqid></control><display><type>article</type><title>Clinical evidence of the relationship between aspirin and breast cancer risk (Review)</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>JACOBO-HERRERA, NADIA J ; PÉREZ-PLASENCIA, CARLOS ; CAMACHO-ZAVALA, ELIZABETH ; GONZÁLEZ, GABRIELA FIGUEROA ; URRUTIA, EDUARDO LÓPEZ ; GARCÍA-CASTILLO, VERÓNICA ; ZENTELLA-DEHESA, ALEJANDRO</creator><creatorcontrib>JACOBO-HERRERA, NADIA J ; PÉREZ-PLASENCIA, CARLOS ; CAMACHO-ZAVALA, ELIZABETH ; GONZÁLEZ, GABRIELA FIGUEROA ; URRUTIA, EDUARDO LÓPEZ ; GARCÍA-CASTILLO, VERÓNICA ; ZENTELLA-DEHESA, ALEJANDRO</creatorcontrib><description>In the search for new therapeutic alternatives against cancer, either as a preventive treatment or for advanced stages, it is common to appeal to well-known drugs used for the treatment of other diseases that may interfere with the metabolic pathways involved in carcinogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) display anticancer activity through the inhibition of the COX-2 enzyme, triggering processes such as apoptosis, a reduction in proliferation and inhibition of carcinogenesis. Breast cancer is a neoplasm with the highest incidence and mortality rate among young women worldwide. Epidemiologic data have shown that drugs such as NSAIDs, particularly aspirin, reduce the relative risk of breast cancer. However, in the subgroup of responsive patients, dose, time and frequency of use have not yet been established. Here, we review the reports published during the last 10 years regarding the relationship between breast cancer and aspirin.</description><identifier>ISSN: 1021-335X</identifier><identifier>EISSN: 1791-2431</identifier><identifier>DOI: 10.3892/or.2014.3270</identifier><identifier>PMID: 24927467</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Aspirin ; Aspirin - administration & dosage ; Aspirin - therapeutic use ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - epidemiology ; Breast Neoplasms - prevention & control ; Cancer therapies ; Care and treatment ; chemoprevention ; Chemotherapy ; Clinical Trials as Topic ; Confidence intervals ; COX-2 ; Cyclooxygenase 2 - metabolism ; Dose-Response Relationship, Drug ; Drug dosages ; Drug therapy ; Female ; Genetic aspects ; Health aspects ; Health risk assessment ; Humans ; inflammation ; Mens health ; Metastasis ; Mortality ; NSAIDs ; PubMed ; Risk factors ; Studies ; Womens health</subject><ispartof>Oncology reports, 2014-08, Vol.32 (2), p.451-461</ispartof><rights>Copyright © 2014, Spandidos Publications</rights><rights>COPYRIGHT 2014 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-dccd72b2a6514dc33135a876ed2dce7edd27eec7126e80894253dd2e7d0a8d5d3</citedby><cites>FETCH-LOGICAL-c486t-dccd72b2a6514dc33135a876ed2dce7edd27eec7126e80894253dd2e7d0a8d5d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24927467$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JACOBO-HERRERA, NADIA J</creatorcontrib><creatorcontrib>PÉREZ-PLASENCIA, CARLOS</creatorcontrib><creatorcontrib>CAMACHO-ZAVALA, ELIZABETH</creatorcontrib><creatorcontrib>GONZÁLEZ, GABRIELA FIGUEROA</creatorcontrib><creatorcontrib>URRUTIA, EDUARDO LÓPEZ</creatorcontrib><creatorcontrib>GARCÍA-CASTILLO, VERÓNICA</creatorcontrib><creatorcontrib>ZENTELLA-DEHESA, ALEJANDRO</creatorcontrib><title>Clinical evidence of the relationship between aspirin and breast cancer risk (Review)</title><title>Oncology reports</title><addtitle>Oncol Rep</addtitle><description>In the search for new therapeutic alternatives against cancer, either as a preventive treatment or for advanced stages, it is common to appeal to well-known drugs used for the treatment of other diseases that may interfere with the metabolic pathways involved in carcinogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) display anticancer activity through the inhibition of the COX-2 enzyme, triggering processes such as apoptosis, a reduction in proliferation and inhibition of carcinogenesis. Breast cancer is a neoplasm with the highest incidence and mortality rate among young women worldwide. Epidemiologic data have shown that drugs such as NSAIDs, particularly aspirin, reduce the relative risk of breast cancer. However, in the subgroup of responsive patients, dose, time and frequency of use have not yet been established. Here, we review the reports published during the last 10 years regarding the relationship between breast cancer and aspirin.</description><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Aspirin</subject><subject>Aspirin - administration & dosage</subject><subject>Aspirin - therapeutic use</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - prevention & control</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>chemoprevention</subject><subject>Chemotherapy</subject><subject>Clinical Trials as Topic</subject><subject>Confidence intervals</subject><subject>COX-2</subject><subject>Cyclooxygenase 2 - metabolism</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>inflammation</subject><subject>Mens health</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>NSAIDs</subject><subject>PubMed</subject><subject>Risk factors</subject><subject>Studies</subject><subject>Womens health</subject><issn>1021-335X</issn><issn>1791-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkVtLxDAQhYMo3t98loAgCnbNrU37uCzeQBBEwbeQTaZutNvUpKv478266w1kBmYYvjNDchDao2TAy4qd-jBghIoBZ5KsoE0qK5oxwelq6gmjGef5wwbaivGJkIQU1TraYKJiUhRyE92PGtc6oxsMr85CawD7GvcTwAEa3Tvfxonr8Bj6N4AW69i54FJtLR4H0LHHRidRwMHFZ3x0m7bA2_EOWqt1E2F3WbfR_fnZ3egyu765uBoNrzMjyqLPrDFWsjHTRU6FNZxTnutSFmCZNSDBWiYBjKSsgJKUlWA5TzOQlujS5pZvo4PF3i74lxnEXj35WWjTSUUrzoqSyIL-UI-6AeXa2vdBm6mLRg0FTUhFhUjU4B8qhYWpM76F2qX5H8HhL8EEdNNPom9mn5_2FzxZgCb4GAPUqgtuqsO7okTNPVQ-qLmHau5hwveXj5qNp2C_4S_Tfg7HLvngrI_fjA8ZZxlJKXLKPwA2f6FU</recordid><startdate>201408</startdate><enddate>201408</enddate><creator>JACOBO-HERRERA, NADIA J</creator><creator>PÉREZ-PLASENCIA, CARLOS</creator><creator>CAMACHO-ZAVALA, ELIZABETH</creator><creator>GONZÁLEZ, GABRIELA FIGUEROA</creator><creator>URRUTIA, EDUARDO LÓPEZ</creator><creator>GARCÍA-CASTILLO, VERÓNICA</creator><creator>ZENTELLA-DEHESA, ALEJANDRO</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201408</creationdate><title>Clinical evidence of the relationship between aspirin and breast cancer risk (Review)</title><author>JACOBO-HERRERA, NADIA J ; PÉREZ-PLASENCIA, CARLOS ; CAMACHO-ZAVALA, ELIZABETH ; GONZÁLEZ, GABRIELA FIGUEROA ; URRUTIA, EDUARDO LÓPEZ ; GARCÍA-CASTILLO, VERÓNICA ; ZENTELLA-DEHESA, ALEJANDRO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-dccd72b2a6514dc33135a876ed2dce7edd27eec7126e80894253dd2e7d0a8d5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Aspirin</topic><topic>Aspirin - administration & dosage</topic><topic>Aspirin - therapeutic use</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - prevention & control</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>chemoprevention</topic><topic>Chemotherapy</topic><topic>Clinical Trials as Topic</topic><topic>Confidence intervals</topic><topic>COX-2</topic><topic>Cyclooxygenase 2 - metabolism</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>inflammation</topic><topic>Mens health</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>NSAIDs</topic><topic>PubMed</topic><topic>Risk factors</topic><topic>Studies</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JACOBO-HERRERA, NADIA J</creatorcontrib><creatorcontrib>PÉREZ-PLASENCIA, CARLOS</creatorcontrib><creatorcontrib>CAMACHO-ZAVALA, ELIZABETH</creatorcontrib><creatorcontrib>GONZÁLEZ, GABRIELA FIGUEROA</creatorcontrib><creatorcontrib>URRUTIA, EDUARDO LÓPEZ</creatorcontrib><creatorcontrib>GARCÍA-CASTILLO, VERÓNICA</creatorcontrib><creatorcontrib>ZENTELLA-DEHESA, ALEJANDRO</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JACOBO-HERRERA, NADIA J</au><au>PÉREZ-PLASENCIA, CARLOS</au><au>CAMACHO-ZAVALA, ELIZABETH</au><au>GONZÁLEZ, GABRIELA FIGUEROA</au><au>URRUTIA, EDUARDO LÓPEZ</au><au>GARCÍA-CASTILLO, VERÓNICA</au><au>ZENTELLA-DEHESA, ALEJANDRO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical evidence of the relationship between aspirin and breast cancer risk (Review)</atitle><jtitle>Oncology reports</jtitle><addtitle>Oncol Rep</addtitle><date>2014-08</date><risdate>2014</risdate><volume>32</volume><issue>2</issue><spage>451</spage><epage>461</epage><pages>451-461</pages><issn>1021-335X</issn><eissn>1791-2431</eissn><abstract>In the search for new therapeutic alternatives against cancer, either as a preventive treatment or for advanced stages, it is common to appeal to well-known drugs used for the treatment of other diseases that may interfere with the metabolic pathways involved in carcinogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) display anticancer activity through the inhibition of the COX-2 enzyme, triggering processes such as apoptosis, a reduction in proliferation and inhibition of carcinogenesis. Breast cancer is a neoplasm with the highest incidence and mortality rate among young women worldwide. Epidemiologic data have shown that drugs such as NSAIDs, particularly aspirin, reduce the relative risk of breast cancer. However, in the subgroup of responsive patients, dose, time and frequency of use have not yet been established. Here, we review the reports published during the last 10 years regarding the relationship between breast cancer and aspirin.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>24927467</pmid><doi>10.3892/or.2014.3270</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1021-335X |
| ispartof | Oncology reports, 2014-08, Vol.32 (2), p.451-461 |
| issn | 1021-335X 1791-2431 |
| language | eng |
| recordid | cdi_proquest_journals_1932680761 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Aspirin Aspirin - administration & dosage Aspirin - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - epidemiology Breast Neoplasms - prevention & control Cancer therapies Care and treatment chemoprevention Chemotherapy Clinical Trials as Topic Confidence intervals COX-2 Cyclooxygenase 2 - metabolism Dose-Response Relationship, Drug Drug dosages Drug therapy Female Genetic aspects Health aspects Health risk assessment Humans inflammation Mens health Metastasis Mortality NSAIDs PubMed Risk factors Studies Womens health |
| title | Clinical evidence of the relationship between aspirin and breast cancer risk (Review) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T14%3A20%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20evidence%20of%20the%20relationship%20between%20aspirin%20and%20breast%20cancer%20risk%20(Review)&rft.jtitle=Oncology%20reports&rft.au=JACOBO-HERRERA,%20NADIA%20J&rft.date=2014-08&rft.volume=32&rft.issue=2&rft.spage=451&rft.epage=461&rft.pages=451-461&rft.issn=1021-335X&rft.eissn=1791-2431&rft_id=info:doi/10.3892/or.2014.3270&rft_dat=%3Cgale_proqu%3EA410769144%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932680761&rft_id=info:pmid/24927467&rft_galeid=A410769144&rfr_iscdi=true |